Alexion Pharmaceuticals, Inc.  

(Public, NASDAQ:ALXN)   Watch this stock  
Find more results for ALXN
131.54
+1.10 (0.84%)
Feb 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 130.00 - 132.46
52 week 109.12 - 162.00
Open 131.37
Vol / Avg. 1.66M/2.23M
Mkt cap 29.79B
P/E 74.75
Div/yield     -
EPS 1.76
Shares 224.61M
Beta 1.39
Inst. own 99%
Feb 1, 2017
Q4 2016 Alexion Pharmaceuticals Inc Earnings Release (Estimated)
Dec 12, 2016
Alexion Pharmaceuticals Inc - New Leadership Appointments - Webcast
Dec 7, 2016
Alexion Pharmaceuticals Inc at Citi Global Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin 11.13% 12.94%
Operating margin 15.30% 21.63%
EBITD margin - 38.55%
Return on average assets 2.79% 3.03%
Return on average equity 4.31% 4.71%
Employees 3,121 -
CDP Score - -

Address

100 College St
NEW HAVEN, CT 06510-3210
United States - Map
+1-203-2722596 (Phone)
+1-203-2718198 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company's marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company's clinical programs include Soliris (eculizumab), ALXN 1101, ALXN 1007, SBC-103, ALXN 1210 and ALXN 5500. It offers Soliris for patients with either paroxysmal nocturnal hemoglobinuria (PNH), a life-threatening and ultra-rare genetic blood disorder, or atypical hemolytic uremic syndrome (aHUS), a life-threatening and ultra-rare genetic disease. Strensiq is a targeted enzyme replacement therapy. It offers Kanuma for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). ALXN 1007 is a humanized antibody designed to target inflammatory disorders.

Officers and directors

Leonard Bell M.D. Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
David R. Brennan Interim Chief Executive Officer, Director
Age: 62
Bio & Compensation  - Reuters
David John Anderson Chief Financial Officer
Age: 67
Bio & Compensation  - Reuters
Clare Carmichael Chief Human Resource Officer, Executive Vice President
Age: 57
Bio & Compensation  - Reuters
John B. Moriarty J.D. Executive Vice President, General Counsel
Age: 49
Bio & Compensation  - Reuters
Martin Mackay Ph.D. Executive Vice President, Global Head - Research and Development
Age: 60
Bio & Compensation  - Reuters
Julie O'Neill Executive Vice President - Global Operations
Age: 50
Bio & Compensation  - Reuters
Carsten Thiel Ph.D. Executive Vice President, Chief Commercial Officer
Age: 53
Bio & Compensation  - Reuters
Edward Miller J.D. Senior Vice President, Global Chief Compliance Officer
Age: 52
Bio & Compensation  - Reuters
Heidi L. Wagner J.D. Senior Vice President - Global Governmental Affairs
Age: 52
Bio & Compensation  - Reuters